Pathological and biochemical effects of therapeutic and supratherapeutic doses of celecoxib in Wistar albino male rats

Drug and Chemical Toxicology

Volumn 33, Issue 4, 2010, Pages 410-414

  Koçkaya, Evrim A ^a   Selmanoǧlu, Güldeniz ^b   Kismet, Kemal ^c   Akay, M Turan ^b  

^a GAZI UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c ANKARA NUMUNE HOSPITAL   (Turkey)

Author keywords

Biochemical effects; Celecoxib; Kidney; Liver; Wistar rat

Indexed keywords

BILIRUBIN; CALCIUM; CELECOXIB; GAMMA GLUTAMYLTRANSFERASE; GLOBULIN; NITROGEN; PHOSPHORUS; PROTEIN; UREA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILIRUBIN BLOOD LEVEL; BIOCHEMISTRY; CALCIUM BLOOD LEVEL; CELL DEGENERATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEGENERATION; DRUG DOSE INCREASE; DRUG EFFECT; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HISTOPATHOLOGY; HYPERPLASIA; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; LIVER FUNCTION; LIVER INJURY; MALE; MICROSCOPY; MONONUCLEAR CELL; NONHUMAN; RAT; UREA BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; BODY WEIGHT; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; KIDNEY; KIDNEY FUNCTION TESTS; LIVER; LIVER FUNCTION TESTS; MALE; ORGAN SIZE; PYRAZOLES; RATS; RATS, WISTAR; SULFONAMIDES; TOXICITY TESTS, CHRONIC;

RATTUS; RATTUS NORVEGICUS;

EID: 77956140376     PISSN: 01480545     EISSN: 15256014     Source Type: Journal    
DOI: 10.3109/01480540903575691     Document Type: Article

References (22)

1. Aldana, L., De Mejia, E. G., Craigmill, A., Tsutsumi, V., Armenmdariz-Borunda, J., Panduro, A., et al. (1998). Cypermethrin increases apo A-1 and apo B mRNA but not hyperlipidemia in rats. Toxicol Lett 95:31-39.
2. Chow, L. W. C., Cheng, C. W. L., Wong, J. L. N., Toi, M. (2005). Serum lipid profles in patients receiving endocrine treatment for breast cancer\the results from the Celecoxib Antiaromatase Neoadjuvant (CAAN) trial. Biomed Pharmacother 59:S302-S305.
3. Chulada, P. C., Tompson, M. B., Mahler, J. F., Doyle, C. M., Gaul, B. W., Lee, C., et al. (2000). Genetic distruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60:4705-4708.
4. Davies, N. M., McLachlan, A. J., Day, R. O., Williams, K. M. (2000). Clinical pharmacokinetics and pharmacodynam-ics of celecoxib: a selective cyclooxygenase-2 inhibitor. Clin Pharmacokinet 38:225-242.
5. Dempke, W., Rie, C., Grothey, A., Schmoll, H. J. (2001). Cyclooxygenase-2: novel target for cancer chemotheraphy. J Cancer Res Clin Oncol 127:411-417.
6. Emery, P., Zeidler, H., Kvien, T. K., Guslandi, M., Naudin, R., Stead, H., et al. (1999). Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised, double-blind comparison. Lancet 354:2106-2111.
7. Grieco, A., Miele, L., Giorgi, A., Civello, I. M., Gasbarrini, G. (2002). Acute cholestatic hepatitis associated with celecoxib. Ann Pharmacother 36:1887-1889.
8. Han, C., Leng, J., Demetris, A. J., Wu, T. (2004). Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2- independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res 64:1369-1376.
9. Hasegawa, K., Ichikawa, W., Fujita, T., Ohno, R., Okusa, T., Yoshinaga, K., et al. (2001). Expression of cyclooxygenase-2 (COX-2) mRNA in human colorectal adenomas. Eur J Cancer 37:1469-1474.
10. Hawkey, C. J. (1999). COX-2 inhibitors. Lancet 353:307-314.
11. Hull, M. A., Booth, J. K., Tisbury, A., Scott, N., Bonifer, C., Markham, A. F., et al. (1999). Cyclooxygenase 2 is upregulated and localized to macrophages in the intestine of Min mice. Br J Cancer 79:1399-1405.
12. Jones, D. A., Carlton, D. P., McIntyre, T. M., Zimmerman, G. A., Prescott, S. M. (1993). Molecular cloning of human prostoglandin endoperoxide synthatase type II and demonstration of expression in response to cytokines. J Biol Chem 208:9049-9054.
13. Maier, T. J., Schilling, K., Schmidt, R., Geisslinger, G., Grosch, G. (2004). Cyclooxygenase-2 (COX-2)-dependent and-inde-pendent anticarcinogenic efects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 67:1469-1478.
14. Marquez-Rosado, L., Trejo-Solis, M. C., Garcia-Cuellar, C. M., Villa-Trevino, S. (2005). Celecoxib, a cyclooxygenase-2 inhibitor, prevents induction of liver preneoplastic lesions in rats. J Hepatol 43:653-660.
15. Masferrer, J. L., Isakson, P. C., Seibert, K. (1996). Cyclooxygenase-2 inhibitors: a new class of anti-infammatory agents that spare the gastrointestinal tract. Gastroenterol Clin N Am 25:363-372.
16. National Research Council. (1996). Guide for the care and use of laboratory animals. Washington, DC: National Academy.
17. O'Beirne, J. P., Cairns, S. R. (2001). Cholestatic hepatitis in association with celecoxib. BMJ 323:23.
18. Prescott, S. M., Fitzpatrick, F. A. (2000). Cyclooxygenase-2 and car-cinogenesis. Biochim Biophys Acta 1470:M69-M78.
19. Ravoori, S., Feng, Y., Neale, J. R., Jeyabalan, J., Srinivasan, C., Hein, D. W., et al. (2008). Dose-dependent reduction of 3,2'-dimethyl-4- aminobiphenyl-derived DNA adducts in colon and liver of rats administered celecoxib. Mutat Res 638:103-109.
20. Sonoshita, M., Takaku, K., Oshima, M., Sugihara, K., Taketo, M. M. (2002). Cyclooxygenase-2 expression in fbrob-lasts and endothelial cells of intestinal polyps. Cancer Res 62:6846-6849.
21. Tiano, H. F., Loftin, C. D., Akunda, J., Lee C. A., Spalding, J., Sessoms, A., et al. (2002). Defciency of either cyclooxy-genase (COX)-1 or COX-2 alters epidermal diferentia-tion and reduces mouse skin tumorigenesis. Cancer Res 62:3395-3401.
22. Wong, B. C., Jiang, X., Fan, X. M., Lin, M. C., Jiang, S. H., Lam, S. K., et al. (2003). Suppression of RelA/p65 nuclear translocation independent of kappaB-alpha degradation by cyclooxygen-ase-2 inhibitor in gastric cancer. Oncogene 22:1189-1197.